(Enlarged Board of Appeal of the European Patent Office) it was: ‘legitimate in principle to allow claims directed to the use of a substance or composition for the manufacture of a medicament for a specified new and inventive therapeutic application, even in a case in which the process of manufacture as such does not differ from known processes using the same active ingredient.’
G 05/83, [1979-85] EPOR B241
European
Cited by:
Cited – Warner-Lambert Company Llc v Generics (UK) Ltd (T/A Mylan) and Another SC 14-Nov-2018
These proceedings raise, for the first time in the courts of the United Kingdom, the question how the concepts of sufficiency and infringement are to be applied to a patent relating to a specified medical use of a known pharmaceutical compound. . .
Lists of cited by and citing cases may be incomplete.
Updated: 12 October 2021; Ref: scu.668408
